UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Diabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.467-477

2014

Volltextzugriff (PDF)

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Diabetes & metabolism, 2016-02, Vol.42 (1), p.25-32

2016

Volltextzugriff (PDF)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

Diabetes, obesity & metabolism, 2013-07, Vol.15 (7), p.642-649

2013

Volltextzugriff (PDF)

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

Diabetic medicine, 2010-12, Vol.27 (12), p.1409-1419

2010

Volltextzugriff (PDF)

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

Diabetic medicine, 2012-09, Vol.29 (9), p.1115-1118

2012

Volltextzugriff (PDF)

Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide

Diabetic medicine, 2016-03, Vol.33 (3), p.391-394

2016

Volltextzugriff (PDF)

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

Diabetes, obesity & metabolism, 2014-08, Vol.16 (8), p.748-756

2014

Volltextzugriff (PDF)

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus : Results from a controlled randomized study

Circulation (New York, N.Y.), 2005-05, Vol.111 (19), p.2525-2531

2005

Volltextzugriff (PDF)

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes

Acta diabetologica, 2013-08, Vol.50 (4), p.587-595

2013

Volltextzugriff (PDF)

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

Diabetes, obesity & metabolism, 2013-12, Vol.15 (12), p.1111-1119

2013

Volltextzugriff (PDF)

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.542-550

2011

Volltextzugriff (PDF)

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2013-06, Vol.15 (6), p.576-579

2013

Volltextzugriff (PDF)

Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients

Hormone and metabolic research, 2009-02, Vol.41 (2), p.123-131

2009

Volltextzugriff (PDF)

Performance of blood glucose meters in compliance with current and future clinical ISO15197 accuracy criteria

Current medical research and opinion, 2014-02, Vol.30 (2), p.185-190

2014

Volltextzugriff (PDF)

The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus

Current medical research and opinion, 2014-05, Vol.30 (5), p.753-760

2014

Volltextzugriff (PDF)

OP8 THE 2-WEEK FASTING GLUCOSE AS A PREDICTOR OF GLYCEMIC RESPONSE TO ONCE-WEEKLY DULAGLUTIDE 1.5 MG

Diabetes research and clinical practice, 2014-11, Vol.106, p.S4-S5

2014

Volltextzugriff (PDF)

Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control

Current medical research and opinion, 2014-10, Vol.30 (10), p.2001-2008

2014

Volltextzugriff (PDF)

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

Diabetes, obesity & metabolism, 2010-05, Vol.12 (5), p.437-441

2010

Volltextzugriff (PDF)

Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes

European journal of endocrinology, 2011-08, Vol.165 (2), p.269-274

2011

Volltextzugriff (PDF)

Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitus

Current medical research and opinion, 2012-01, Vol.28 (1), p.15-21

2012

Volltextzugriff (PDF)

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Atherosclerosis, 2008-03, Vol.197 (1), p.311-317

2008

Volltextzugriff (PDF)

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

Current medical research and opinion, 2006-06, Vol.22 (6), p.1211-1215

2006

Volltextzugriff (PDF)

P330 Effets du lixisénatide vs liraglutide sur l’équilibre glycémique, la vidange gastrique et les critères de tolérance du traitement dans le diabète de type 2 (DT2) traité de façon optimisée par insuline glargine ± metformine

Diabetes & metabolism, 2015-03, Vol.41, p.A117-A117

2015

Volltextzugriff (PDF)

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study

Diabetes, obesity & metabolism, 2009-05, Vol.11 (5), p.464-471

2009

Volltextzugriff (PDF)

P1060 Interférence de l’hématocrite sur les mesures de glycémie par glucomètre (étude de laboratoire)

Diabetes & metabolism, 2013-03, Vol.39, p.A45-A46

2013

Volltextzugriff (PDF)

1 – 25 von 2.973

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.038)
Mit Volltextzugriff
(2.312)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.080)
Life Sciences & Biomedicine
(795)
Humans
(695)
Male
(384)
Female
(363)
Biological And Medical Sciences
(288)
Middle Aged
(274)
Adult
(246)
Physical Sciences
(229)
Aged
(197)
Medical Sciences
(194)
Technology
(132)
Endocrinology & Metabolism
(131)
Physics
(129)
Animals
(124)
Chemistry
(122)
Social Sciences
(118)
Fundamental And Applied Biological Sciences. Psychology
(102)
Adolescent
(95)
Exact Sciences And Technology
(95)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(20)
... seit 30 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus : Results from a controlled randomized study

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients

Performance of blood glucose meters in compliance with current and future clinical ISO15197 accuracy criteria

The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus

OP8 THE 2-WEEK FASTING GLUCOSE AS A PREDICTOR OF GLYCEMIC RESPONSE TO ONCE-WEEKLY DULAGLUTIDE 1.5 MG

Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes

Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitus

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

P330 Effets du lixisénatide vs liraglutide sur l’équilibre glycémique, la vidange gastrique et les critères de tolérance du traitement dans le diabète de type 2 (DT2) traité de façon optimisée par insuline glargine ± metformine

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study

P1060 Interférence de l’hématocrite sur les mesures de glycémie par glucomètre (étude de laboratoire)

Suchergebnisse filtern